Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 276

Sort by

Sort Order Select

Journal Articles

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

Blood blood.2024027948.

https://doi.org/10.1182/blood.2024027948

Published: 2025

Includes: Supplemental data

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 4601.

https://doi.org/10.1182/blood-2024-204040

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Blood (2024) 144 (Supplement 1): 841.

https://doi.org/10.1182/blood-2024-204042

Published: 2024

Journal Articles

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Nicholas J. Short, Hagop Kantarjian, Nitin Jain, Koichi Takahashi, Ken Furudate, Jayastu Senapati, Fadi G. Haddad, Omer Karrar, Tapan M. Kadia, Kelly S. Chien, Koji Sasaki, Eitan Kugler, Rebecca Garris, Farhad Ravandi, Elias Jabbour

Blood (2024) 144 (Supplement 1): 837.

https://doi.org/10.1182/blood-2024-206602

Published: 2024

Journal Articles

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Alex Bataller, Hagop M. Kantarjian, Alexandre Bazinet, Jayastu Senapati, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 56.

https://doi.org/10.1182/blood-2024-202620

Published: 2024

Journal Articles

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Edward Ayoub, David Lehotzky, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Gad Getz, Michael Andreeff

Blood (2024) 144 (Supplement 1): 61.

https://doi.org/10.1182/blood-2024-211845

Published: 2024

Journal Articles

Clonal Hematopoiesis: A Global Health Perspective on CH Prevalence in Uganda Versus the United States

Ajibike Lapite, James Decuir, Bradley E. Aouizerat, Jeremy J Martinson, Koichi Takahashi, Katherine Y. King

Blood (2024) 144 (Supplement 1): 5650.

https://doi.org/10.1182/blood-2024-208751

Published: 2024

Journal Articles

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Courtney D. DiNardo, Kelly S. Chien, Jillian Mullin, Danielle Hammond, Jeremy Ramdial, Tapan M. Kadia, Fadi G. Haddad, Musa Yilmaz, Koji Sasaki, Ghayas C. Issa, Koichi Takahashi, Elizabeth J. Shpall, Farhad Ravandi, Naval Daver, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1527.2.

https://doi.org/10.1182/blood-2024-208771

Published: 2024

Journal Articles

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Blood (2024) 144 (Supplement 1): 2896.

https://doi.org/10.1182/blood-2024-198541

Published: 2024

Journal Articles

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Blood (2024) 144 (Supplement 1): 2883.

https://doi.org/10.1182/blood-2024-200387

Published: 2024

Journal Articles

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood (2024) 144 (Supplement 1): 1855.

https://doi.org/10.1182/blood-2024-211110

Published: 2024

Journal Articles

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

Blood (2024) 144 (Supplement 1): 1816.

https://doi.org/10.1182/blood-2024-212052

Published: 2024

Journal Articles

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Blood (2024) 144 (Supplement 1): 219.

https://doi.org/10.1182/blood-2024-200393

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1 -Mutated Myeloid Malignancies

Blood (2024) 144 (Supplement 1): 642.

https://doi.org/10.1182/blood-2024-201970

Published: 2024

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia

Jayastu Senapati, Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Tapan M. Kadia, Koji Sasaki, Yesid Alvarado-Valero, Koichi Takahashi, Courtney D. DiNardo, Naval Daver, Guillermo Garcia-Manero, Farhad Ravandi, Jovitta Jacob, Rebecca Garris, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2024-208742

Published: 2024

Journal Articles

Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update

Jayastu Senapati, Elias Jabbour, Nitin Jain, Fadi G. Haddad, Guillermo Garcia-Manero, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Koji Sasaki, Courtney D. DiNardo, Koichi Takahashi, Rebecca Garris, Jovitta Jacob, Yesid Alvarado Valero, Guillermo Montalban-Bravo, Nicholas J. Short, Hagop Kantarjian

Blood (2024) 144 (Supplement 1): 1441.

https://doi.org/10.1182/blood-2024-208824

Published: 2024

Journal Articles

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood (2024) 144 (Supplement 1): 6126.

https://doi.org/10.1182/blood-2024-207413

Published: 2024

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab in Previously Untreated Myelodysplastic Syndrome

Characteristics and Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) and FLT3 -Tyrosine Kinase Domain (TKD) Mutations

Blinatumomab and Ponatinib for Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results and Predictors of Relapse

Phase II Study of Cladribine with Low Dose Cytarabine and Venetoclax Alternating with Azacytidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Clonal Hematopoiesis: A Global Health Perspective on CH Prevalence in Uganda Versus the United States

Phase 1b/2 Study of Decitabine and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Olutasidenib for Patients with Relapsed/Refractory AML, High Risk MDS, or Newly Diagnosed AML Not Eligible for Chemotherapy with an IDH1 Mutation

Fully Oral Combination of Decitabine/Cedazuridine (ASTX727) Plus Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Ineligible for Intensive Chemotherapy

Clinical Outcomes Using Frontline “Triplet” Regimens for Newly Diagnosed IDH -Mutated Acute Myeloid Leukemia (AML): A Pooled Analysis of Two Phase Ib/2 Clinical Trials

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10 -4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Hematologic Malignancies: A 2024 Update

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies Is Established Early during Treatment in IDH1 -Mutated Myeloid Malignancies

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia

Low Intensity Mini-Hypercvd (mHCVD), Inotuzumab Ozogamicin (Ino) with/without Blinatumomab (Blina) in Older Patients with Newly Diagnosed Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (B-ALL): 10 Years Update

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only